Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Purchased by Systematic Financial Management LP

Systematic Financial Management LP raised its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 540.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 397,474 shares of the life sciences company’s stock after acquiring an additional 335,424 shares during the period. Systematic Financial Management LP owned approximately 0.50% of Integra LifeSciences worth $11,582,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of IART. Blue Trust Inc. raised its position in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 444 shares during the period. CWM LLC boosted its stake in shares of Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares in the last quarter. Valley National Advisers Inc. purchased a new stake in shares of Integra LifeSciences in the first quarter valued at $63,000. Canada Pension Plan Investment Board purchased a new stake in shares of Integra LifeSciences in the second quarter valued at $114,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Integra LifeSciences by 58.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after purchasing an additional 1,711 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $17.87 on Monday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. Integra LifeSciences Holdings Co. has a 52 week low of $16.96 and a 52 week high of $45.42. The firm has a fifty day moving average of $21.33 and a two-hundred day moving average of $27.14. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of 35.74, a PEG ratio of 0.60 and a beta of 1.10.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $418.20 million during the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.71 EPS. As a group, equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IART. Morgan Stanley increased their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Citigroup lowered their price target on Integra LifeSciences from $23.00 to $20.00 and set a “sell” rating on the stock in a research report on Thursday, August 22nd. BTIG Research lowered their price target on Integra LifeSciences from $22.00 to $20.00 and set a “sell” rating on the stock in a research report on Wednesday, August 28th. Truist Financial decreased their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a research report on Tuesday, July 30th. Finally, JMP Securities decreased their target price on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.